Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capac...
Authors:
Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura and Takafumi Suda
Citation:
BMC Pulmonary Medicine
2021
21:221
Content type: Research
Published on: 12 July 2021